ST生物(000504.SZ)子公司與上海康佺簽署長期供貨合作框架協議
格隆匯10月22日丨ST生物(000504.SZ)公佈,2020年10月20日,公司全資子公司南華幹細胞再生醫學臨牀轉化研究中心有限責任公司(以下稱“南華幹細胞轉化”)與上海康佺企業發展有限公司(以下簡稱“上海康佺”)簽署《長期供貨合作框架協議》,就上海康佺與南華幹細胞轉化建立長期購銷合作關係的有關事宜,達成一致。
上海康佺確定南華幹細胞轉化為專用醫療設備、耗材的指定供應商,除其客户指定使用其他品牌產品外,在同檔次的產品中,上海康佺優先考慮華幹細胞轉化的產品。南華幹細胞轉化亦視上海康佺為長期合作伙伴,優先考慮上海康佺需求。
具體協議以訂單為準。南華幹細胞轉化按上海康佺的採購訂單提供產品和服務。上海康佺收貨後按協議約定向南華幹細胞轉化支付貨款。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.